Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

simtuzumab

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

National Institute for Health and Care Excellence NICE logo

NICE opens consultation on Gilead’s leukaemia drug

Comes after the Institute rejects the treatment in new draft guidance

- PMLiVE

NHS England sets up new £190m hep C fund

Will see patients gain access to treatments from Gilead and AbbVie

Gilead Sciences

Humira remains top pharma product, but Sovaldi closes in

AbbVie’s blockbuster may be bumped to second place this year

- PMLiVE

Merck KGaA, Threshold gain FDA fast-track review

Industry partners hope their new cancer drug will be approved by the end of the year

- PMLiVE

WHO warns on hepatitis C drug pricing

The global health body adds new therapies to its ‘essential medicines’ list

- PMLiVE

Baxter and Merrimack file pancreatic cancer drug in EU

MM-398 is thought to help direct the active drug into tumours

- PMLiVE

Harvoni sales rocket in first quarter

Gilead’s new hepatitis C pill generates stellar revenue

ABPI London offices

Pharma must engage on the affordability question, says ABPI

UK pharma trade body says the industry must be willing to discuss drug pricing

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

Gilead under fire for Sovaldi anti-diversion policy

Accused as generic versions of the drug start to reach the market

- PMLiVE

Novartis knocks Pfizer off sales leader board

Swiss firm takes US giant’s crown as diversification programme and pipeline come to fruition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links